Limited predictable long noncoding RNA (lncRNA) signature was reported in tamoxifen resistance among estrogen receptor (ER)-positive breast cancer (BC) patients. The aim of this study was to identify and assess prognostic lncRNA signature to predict recurrence among ER-positive BC patients treated with tamoxifen. Cohorts from Gene Expression Omnibus (GEO) (n = 298) and The Cancer Genome Atlas (TCGA) (n = 160) were defined as training and validation cohort, respectively. BC relapse associated lnRNAs was identify within training cohort, and the predictable value of recurrence was assessed in both cohorts. A total of 11lncRNAs were recognized to be associated with relapse free survival (RFS) of ER-positive BC patients receiving tamoxifen, who were divided into low-risk and high-risk group on basis of relapse risk scores (RRS). Multivariate cox regression analyses revealed that the RRS is an independent prognostic biomarker in the prediction of ER-positive BC patients' survival. GSEA indicated that high-risk group was associated with several signaling pathways in processing of BC recurrence and metastasis such as PI3K-Akt and Wnt signaling. Our 11-lncRNA based classifier is a reliable prognostic and predictive tool for disease relapse in BC patients receiving tamoxifen.
LncRNA Expression Data Processing and Profile Mining. Raw microarray data files of GSE17705
was retrieved from GEO database, and we adjusted the background using the Robust Multichip Average (RMA) algorithm actualized by R package 'affy' 37 . LncRNA profile mining was mainly referenced to method proposed by Du et al. 38 . Briefly, we mapped the probe sets IDs from Affymetrix HG-U133A to human genome, and SeqMap 39 was used to avoid mismatching. Then, the chromosomal positions according these probe IDs were used to (26) 124 (78) Negative 22 (7) 19 (12) NR 199(67) 17 (10) identify corresponding positions of LncRNA. Finally, 569 annotated lncRNA transcripts with 742 corresponding Affymetrix probe IDs were generated. The expression profiling of multiple probe IDs mapped to unique LncRNA was calculated as arithmetic mean of the values. Similarly, we downloaded expression information from TCGA BC RNA-sequencing database of LncRNA using The Atlas of Noncoding RNAs Cancer (TANRIC) 40 , and then annotated each included sample according to barcode ID.
Statistical. To identify LncRNAs predictive of a RFS, a univariate Cox proportional hazards regression analysis was performed to assess relationship between expression of LncRNAs level and RFS among training series, which was considered statistically significant if their P values were less than or equal to 0.01. Then we conducted stepwise multivariate Cox hazard regression analysis using above LncRNAs to yield a set of genes ultimately that had independent effects on RFS, and a relapse risk score (RRS) for predicting RFS was calculated by taking into account the expression of gene and correlation coefficient as following:
where n is the number of selected LncRNAs, E is the expression level of LncRNAs and C is the coefficient generated from multivariate Cox regression. Considering the practice of this prognostic model, we assigned each patient a RRS combined linearly by expression of significant LncRNAs and their respective coefficients. Then, we divided training and validation cohort into low-risk group and high-risk group according to RRS, respectively, and the third quantile RRS is defined as the cut-off value depended on receiver operating characteristic (ROC). RFS curve was estimated between high-risk group and low-risk group using Kaplan Meier method, and log-rank tests were used to evaluate the differences between them. ROC curve was conducted to assess sensitivity and specificity of this RRS on basis of selected LncRNAs. To further analysis the independent association between RRS and RFS, univariate and multivariate Cox proportional hazards regressions were applied using clinicopathological factors and RRS. This action was executed only within TCGA cohort, which had relatively comprehensive clinical data. Additionally, a nomogram including factors mentioned before was constructed, and validated internally through 200 bootstrap resamples. Concordance index (C-index) was calculated for the evaluation of the performance of predicting and discrimination ability by test concordance between predicted probability and actual outcome. Similarly, to achieve visualization, calibration of this nomogram was conducted by comparing Gene Set Enrichment Analysis. To reversely validate the functional prediction of identified lncRNAs set, we conducted gene set enrichment analysis (GSEA) based on GSE17705 cohort. GSEA was performed by the JAVA program (http://www.broadinstitute.org/gsea) through MSigDB C2 CP: Canonical pathways gene set collection (1320 gene sets available). Gene sets with a false discovery rate (FDR) value < 0.05 after performing 1,000 permutations were considered to be significantly enriched 41 , and selected recurrence or metastasis related enrichment results were visualized by Cytoscape (version 2.8.2) and the Enrichment Map software 42 . All P or adjusted P values reported were two-sided, which less than 0.05 were considered statistically significant. All of statistical tests were done with SPSS 23 (SPSS, Chicago, IL, USA), R software (version 3.2.5) with Bioconductor 43 and rms packages.
Results

Identification of LncRNA genes associated with relapse in the training cohort. GES17705
(n = 298) was used to explore prognostic LncRNAs, which was larger database in this study. A univariate Cox proportional hazards regression analysis was performed to identify whether each LncRNA gene expression level was associated with RFS, and we identified a set of 23 genes (PINK1.AS, RP11.932O9.9, RP11.259N19.1, RP3.339A18.6, KLF3.AS1, LINC00339, LINC00472, RP11.351I21.11, RP11.72I8.1, KB.1460A1.5, RP1.223E5.4, PKD1P6.NPIPP1, RP11.499P20.2, PDCD4.AS1, RP6.74O6.2, KB.1592A4.15, PP14571, RP11.69E11.4, MGC16275, RP11.105C19.2, AC093110.3, LLNLR.284B4.1, RP11.488C13.7) were significantly correlated with RFS (p < 0.05, Supplementary Table S1 ). Stepwise multivariate Cox proportional hazards regression analysis was conducted to select final 11 included LncRNAs, including PINK1.AS, RP11.259N19.1, KLF3.AS1, LINC00339, LINC00472, RP11.351I21.11, KB.1460A1.5, PKD1P6.NPIPP1, PDCD4.AS1, KLF3.AS1 PP14571, RP11.69E11.4. Among those gens, the negative coefficients for the eight genes (PINK1.AS, KLF3.AS1, LINC00339, LINC00472, RP11.351I21.11, PKD1P6.NPIPP1, PDCD4.AS1, RP11.69E11.4) indicated high level of expression were associated with longer RFS. The positive coefficients for remaining 3 genes (RP11.259N19.1, KB.1460A1.5, PP14571) revealed that high expression of them was associated with shorter RFS. Accordingly, a RRS was After conducting ROC analysis, the prognostic power of 3-year or 5-year RFS predicted by eleven-LncRNAs risk score was evaluated within GSE17705. As shown in Fig. 2A , the sensitivity, specificity of RRS were 0.67 and 0.74, respectively, and the area under curves (AUCs) of RRS for prediction 3-year and 5-year RFS were 0.71 and 0.77, respectively, indicating that the performance of eleven-LncRNAs based RRS was mediocre. The training cohort was divided into high-risk (n = 74) and low-risk group (n = 224) according to the third quartile risk score as the cut-off value. Kaplan-Meier analysis revealed that patients in high-risk group had significantly shorter median DFS than those in low-risk group (log-rank test P < 0.0001) (Fig. 2C ).
The 11-lncRNA signature and the patients' survival in the external validation cohort. To validate the prognostic power of the eleven-lncRNA signature for the prediction of relapse risk, the TCGA cohort (n = 160) use the same formula to classify patients into high-risk group (n = 40) and low-risk group (n = 120) using the third quartile RRS of validation series as the cut-off point. ROC suggested that AUC of 0.71 and 0.69 revealed general predictive performances of 3-year and 5-year RFS, respectively (Fig. 2B ). In the consistence with the findings described above, patients in the high-risk group had significantly shorter median RFS than those in the low-risk group (log-rank test P < 0.0001) (Fig. 2D) . The distribution of the eleven-lncRNAs risk score, the relapse status of the BC patients and the lncRNA expression signature were also obtained ( Fig. 3) . To further test whether the 11-lncRNA signature was independent of other clinicopathological variables, we conducted multivariate Cox regression analysis using RRS, age, AJCC stage, chemotherapy status and LNR as covariables in the TCGA cohort (n = 160). The results suggested that the 11-lncRNA signature risk score (RRS) maintained a significant correlation with RFS after adjustment for other clinical variables (HR = 3.56, 95%CI = 1.46-8.66) ( Table 2) , indicating that RRS is an independent relapse predictive factor. Additionally, a nomogram was constructed using above variables, which was shown as Fig. 4A . Corresponding ROC analyses were conducted according to 3-year and 5-year RFS (Fig. 4B) , and yielded AUC of 0.71 and 0.73 indicated that RRS combined clinicopathological variables can generally predict 3-year and 5-year RFS, respectively. In internal validation, C-indexes for the nomograms to predict RFS were 0.78 (95% CI, 95%CI = 0.67 to 0.89), whose calibration plots for prediction of 3-year and 5-year RFS were presented in Fig. 4C. Functional prediction of the 11-lncRNA signature. To infer the potential function of the 11-LncRNAs signature in prediction of BC relapse, we performed GSEA to identify associated biological processes and signaling pathways based on GSE17705 datasets. The gene sets from high-risk group compared with low-risk defined before was employed to select significant individuals (adjusted P < 0.05) ( Fig. 5A ) ( Supplementary Table S2 ), and then relapse or metastasis related sets of them were visualized as interaction networks with Cytoscape and Enrichment Map (Fig. 5B) . Several relapse or metastasis-related pathways like PI3K-Akt signaling, Wnt signaling and focal adhesion were found from up-regulation gene sets (Fig. 5B ).
Discussion
In this study, we developed and validated a novel prognostic tool based on 11-lncRNAs to improve the prediction of disease recurrence for ER-positive BC patients who were primarily treated with tamoxifen as unique endocrine therapy. Our results showed that this tool can successfully classify patients into high-risk and low-risk groups, and differences in 3-year/5-year RFS were identified in training and validation cohorts. In addition, the 11-lncRNAs signature was proved to be independent from other clinicopathological variables, and GSEA was conducted on basis of RRS to validate the functional differences. A comprehensive and practical nomogram was construct to predict the individualized recurrence, which provided opportunities for clinicians to classify the patients according to these valid tools.
LncRNA LINC00472 is located on chromosome 6q13, and the verified transcript has 2,933 bp. Previous in vitro study with meta-analysis suggested that LINC00472 is a tumor suppressor in breast cancer, whose potential prognostic and predictive value should be evaluated 44 . Similarly, Shen et al. indicated that LINC00472 expression in breast tumors predicted the recurrence of grade II breast cancer 45 . Interestingly, high expression of LINC00472 was often more frequently in low grade and early stage epithelial ovarian cancer compared to high grade tumors and late stage 46 . Moreover, integrated analysis of LncRNA-associated competing endogenous RNAs (ceRNAs) network revealed that LINC00472 was positively correlated with OS of lung adenocarcinoma, and the correlation between LINC00472 and AFAP1-AS1, one of the most common biomarkers to predict the outcomes of cancer patients, was also confirmed 47, 48 . LncRNA KB.1460A1.5 was only proposed in Alzheimer's disease, suggesting this lncRNA with high topological features in the intracellular neurofibrillary tangles may play an important role in Alzheimer's disease. Unexpectedly, related reports were not found in field of oncology. Among the 11 LncRNAs, 15 . LncRNA UCA1 could enhance tamoxifen resistance via inhibiting mTOR signaling pathway, activating wnt/β-catenin signaling pathway, or through a miR-18a-HIF1α regulatory feedback loop 16, 55, 56 . LncRNA HOTAIR could promote the ligand-independent ER activities and thereby contribute to tamoxifen resistance 57 .
Accumulating evidences indicate that the altered expression of ERα, crosstalk with other signaling like HER-2, PI3K and MAPK signaling, mutation of ESR1 and decreased metabolism of the drug may contribute to the acquiring resistance of tamoxifen 8, [58] [59] [60] , of which the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway was identified within results of GSEA in this study. PI3K/Akt and mTOR are two important signaling pathways controlling series of biological processes like cell growth and proliferation, apoptosis, cell-cycle, DNA repair, angiogenesis and glucose metabolism 61 . Ample preclinical studies have indicated that PI3K/Akt/mTOR signaling pathway is co-related with endocrine resistance. The crosstalk between ER and PI3K/Akt/mTOR signaling pathway is a key mechanism by which tamoxifen resistance happens. Yamnik, R. L. et al. found that S6 kinase 1, a substrate of mTOR complex 1 (mTORC1) could phosphorylate the function domain 1 of ER, which leaded to an estrogen-independent activation of the ER-α, thereby resulting in tamoxifen resistance 62 . Otherwise, clinical data showed that the activation of Akt or reduction of PTEN, a tumor suppressor mediating dephosphorylation of PIP3 to PIP2, were associated with tamoxifen resistance in both metastatic and recurrent breast cancer patients 63, 64 . Everolimus, a mTOR inhibitors, has been approved by FDA for the treatment of hormone receptors positive and HER2 negative advanced postmenopausal breast cancer patients, hoping to overcome or slowdown the development of endocrine resistance.
So far, a serious of studies have demonstrated that the wnt/β-catenin signaling pathway is co-related with embryogenesis, self-renewal of adult tissues and tumorigenesis via controlling cell cell morphology, differentiation, proliferation, migration, apoptosis, and even stem cell self-renewal [65] [66] [67] [68] [69] [70] [71] . And the accumulation of β-catenin in the nucleus or cytoplasm has been found in approximately 50% of breast cancers, which predicted a poor prognosis 72 . Meanwhile, wnt/β-catenin has the potential to promote cancer malignant development through motivating the EMT process to facilitate cancer metastasis or inducing therapeutic resistance 73, 74 . Interestingly, lncRNA HNF1A-AS1, lncRNA CCND2-AS1, lncRNA CRNDE, lncRNA CASC2 were revealed that promotional effects on cell proliferation via activation of Wnt/β-catenin cascade in osteosarcoma, glioma, colorectal cancer and bladder cancer were documented, respectively [75] [76] [77] [78] . Additionally, lncRNA UCA1 promotes epithelial-mesenchymal transition of BC cells via enhancing Wnt/β-catenin signaling pathway to facilitate its metastasis 79 , and better reactions to tamoxifen through inhibiting Wnt/β-catenin pathway were found when knock-downing of lncRNA UCA1 could 56 . Some limitations of our study should be acknowledged. Firstly, GSE17705 data sets included in this study was profiled through Affymetrix Human Genome U133A Array, and only part of possible lncRNAs were mined. The incomplete candidate lncRNAs maybe cannot represent the whole biological function of this noncoding RNA, and more large-scale studies were urgently needed to validate reliability of our model. Secondly, eligible participants from two cohorts all received tamoxifen as primarily endocrine therapy, but status and duration of this prescription was poorly reported. The GSE17705 cohort involved 298 BC patients treated with 5-year tamoxifen, whereas TCGA cohort was identified by therapy data, which is one of possible reasons of imperfect validation. Lastly, no experimental validation was acquired to reveal the underlying mechanisms of 11-lncRNAs based prognostic model, and further experimental studies were needed to supply the better understanding of this 11-lncRNAs signature.
In conclusion, our findings showed that the 11-lncRNA based classifier is a reliable prognostic and predictive tool for disease relapse in BC patients receiving tamoxifen, which is independent from traditional clinicopathological factors. Developed nomograms is also available to predict whether patients can benefit from tamoxifen therapy, which are valid tools to illustrate the visualized results.
